Results 161 to 170 of about 516,620 (290)

BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort

European Journal of Haematology, EarlyView.
ABSTRACT Objectives B‐cell maturation antigen (BCMA)‐targeted therapies have recently transformed the management of relapsed or refractory multiple myeloma (RRMM). This study aimed to evaluate their implementation and real‐world impact within EMMY, a French longitudinal cohort. Methods Patients initiating a fourth or later line of therapy (L4+) between
Titouan Cazaubiel, Olivier Decaux, Aurore Perrot, Bruno Royer, Karim Belhadj‐Merzoug, Margaret Macro, Laure Vincent, Lionel Karlin, Arthur Bobin, Thomas Chalopin, Mohamad Mohty, Laurent Frenzel, Julie Gay, Cécile Sonntag, Jean Fontan, Olivier Allangba, Cyrille Touzeau, Hélène Demarquette, Jean‐Valère Malfuson, Claire Jouzier, Stéphane Darre, Benoit Bareau, Ariane Boumendil, Cyrille Hulin, on behalf of EMMY and the IFM group   +24 more
wiley   +1 more source

Claudin 18.2 Targeting: A Pan-Cancer Perspective. [PDF]

Clin Cancer Res
Nikanjam M, Pérez-Granado J, Gramling MW, Larvol B, Kurzrock R.   +4 more
europepmc   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Patient Preferences for the Treatment of Haemophilia A and B in France

Haemophilia, EarlyView.
ABSTRACT Introduction Haemophilia impacts health and quality of life. Advances in treatments such as factor replacement therapy (FRT), bispecific monoclonal antibody (BS‐mAb), gene therapy (GT), rebalancing treatment and high sustained factor necessitate understanding patient preferences to inform therapeutic strategies. Aim This study quantified trade‐
Yesim Dargaud, Yasmine Fahfouhi, Monia Ezzalfani, Astrid Foix Colonier, Alaeddine Sidhom, Aline Gauthier, Jérémie Rudant, Meriem Kessouri, Nicolas Giraud, Benoît Guillet, Anaïs Reynaud   +10 more
wiley   +1 more source

ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window. [PDF]

Mol Cancer Ther
Lee B, Park HJ, Yoo BM, Kim H, Seo A, Hong Y, Lee YS, Yeom D, Son YG, Eom J, Song D, Sung B, Ahn J, Kim J, You WK, Lee SH, Jung J.   +16 more
europepmc   +1 more source

Physical Activity and Sedentary Behaviour in Children With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Physical activity (PA) is vital in child development, while inactivity remains a leading contributor to global mortality. Therapeutic advances have enabled greater PA in boys with haemophilia (BwH), yet robust UK data on objectively measured PA and sedentary behaviour (SB) across severities are limited.
Melanie Bladen, Lucy Alderson, Eleanor Main, Mario Cortina‐Borja   +3 more
wiley   +1 more source

Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1. [PDF]

Front Immunol
Zettl I, Ellinger I, Zghaebi M, Jance S, Izewski V, Drescher A, Breiteneder H, Röck M, Tollinger M, Eckl-Dorna J, Tillib SV, Flicker S.   +11 more
europepmc   +1 more source

Current State of Moderate Congenital Haemophilia A and the Need for Preventive Treatment

Haemophilia, EarlyView.
ABSTRACT Introduction The severity of haemophilia A is classified by the degree of factor VIII (FVIII) deficiency, rather than by clinical manifestations. However, FVIII activity alone does not necessarily accurately reflect clinical severity such as bleeding tendency, and patients with mild‐to‐moderate haemophilia A can experience significant disease ...
Masahiro Takeyama, Atsuki Yamashita, Tomoko Yamaguchi, Takahiro Ito, Yui Sugawara, Akiko Ioka, Tazuko Tokugawa   +6 more
wiley   +1 more source

A view from the periphery: trial design, commercial competition, and the access gap in multiple myeloma. [PDF]

Oncologist
Baysal M, Akpınar S.
europepmc   +1 more source

Bispecific antibody toxicities

Canadian Medical Association Journal
Britto, Joanne, Mian, Hira, Davies, Gwynivere A., Balitsky, Amaris K.   +3 more
openaire   +2 more sources